

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Medlive Technology Co., Ltd.

醫脈通科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2192)

VOLUNTARY ANNOUNCEMENT SHARE PURCHASE BY DIRECTOR

The board of directors (the “**Board**”) of Medlive Technology Co., Ltd. (the “**Company**”) was informed by Ms. Tian Liping (“**Ms. Tian**”), Chairwoman, Chief Executive Officer, an executive director and one of the controlling shareholders of the Company, that on 29 March 2022, 30 March 2022 and 31 March 2022, Ms. Tian has acquired a total of 356,500 shares of the Company (the “**Shares**”) on the market for an aggregate consideration of approximately HK\$2,690,630 (representing an average price of approximately HK\$7.55 per Share) (the “**Acquisition**”). Immediately following the Acquisition, Ms. Tian’s interests in the Shares are as follows:

Number of Shares/ interests held	Nature of interests held	Approximate percentage of Shares/interests in the total issued share capital of the Company as at the date of this announcement
356,500	Beneficial interest	0.05%
267,540,000	Interest in controlled corporation*	37.48%
10,138,000	Beneficial interest**	1.42%
100,000	Interest of spouse***	0.01%

* Ms. Tian holds 48% of Tiantian Co., Limited which directly holds 267,540,000 Shares.

** Ms. Tian was granted share options to subscribe for 10,138,000 Shares under the pre-IPO share option scheme adopted by the Company on 29 March 2021 (the “**Pre-IPO Share Option Scheme**”).

*** Ms. Tian is deemed to be interested in the share options granted to her spouse, Mr. Zhang Xiaofeng, to subscribe for 100,000 Shares under the Pre-IPO Share Option Scheme.

The Acquisition fully demonstrates the confidence of Ms. Tian, as the Chairwoman and Chief Executive Officer of the Company, in the overall development prospects and growth potential of the Company as 356,500 Shares is the maximum number of Shares that Ms. Tian can purchase without breaching the minimum public float of the Company of 24.98%.

Based on the information available to the Company and to the best knowledge of the Board, the Company has maintained sufficient public float of the issued Shares following the Acquisition and as at the date of this announcement. For details of the minimum public float of the Company, please refer to the section headed “Waivers and Exemptions from Strict Compliance with the Listing Rules and the Companies (Winding Up and Miscellaneous Provisions) Ordinance” in the prospectus of the Company dated 30 June 2021 and the announcement of the Company dated 8 August 2021.

Shareholders and potential investors of the Company are advised to exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Medlive Technology Co., Ltd.
Tian Liping
Chairwoman and Chief Executive Officer

Hong Kong, 31 March 2022

As of the date of this announcement, the Board comprises Ms. Tian Liping, Mr. Tian Lixin, Mr. Tian Lijun and Ms. Zhou Xin as executive Directors; Mr. Eiji Tsuchiya and Dr. Li Zhuolin as non-executive Directors; and Mr. Richard Yeh, Dr. Ma Jun and Ms. Wang Shan as independent non-executive Directors.